22 July 2020>: Clinical Research
Phospholipase Cɛ Regulates Prostate Cancer Lipid Metabolism and Proliferation by Targeting AMP-Activated Protein Kinase (AMPK)/Sterol Regulatory Element-Binding Protein 1 (SREBP-1) Signaling Pathway
Yongbo Zheng 1ABCDEF* , Jiajia Jin 2ABCDF* , Yingying Gao 3ACF , Chunli Luo 4AG , Xiaohou Wu 1AG* , Jiayu Liu 1ABCDE*DOI: 10.12659/MSM.924328
Med Sci Monit 2020; 26:e924328
Table 1 Demographic and clinical characteristics of patients.
Characteristics | Overall | PLCɛ | ||
---|---|---|---|---|
Positive (%) | Negative (%) | |||
Prostate cancer | 60 | 41 (68.3%) | 19 (31.7%) | |
Age of patients with PCa (years) | ||||
Median | 64 | 65 | 63–68 | P=0.165* |
Quartiles 25–75 | 62–68 | 63–69 | 61 | |
Histological stage | ||||
Ta–T1 | 16 | 6 | 10 | ** |
T2–T4 | 44 | 35 | 9 | |
Gleason score | ||||
21 | 12 | 9 | P=0.787** | |
≥7 | 39 | 24 | 15 | |
PSA of patients with PCa (μg/l) | ||||
Median | 177 | 178 | 155 | P=0.546* |
Quartiles 25–75 | 52.1–490 | 65.7–283.5 | 41.6–491.6 | |
Metastases in PCa | ||||
Bone | 23 | 20 | 3 | ** |
Visceral | 20 | 18 | 2 | ** |
* Mann-Whitney test; ** Chi-square statistical significance numbers indicated in bold font. PSA – prostate-specific antigen. |